Emergent BioSolutions Inc. announced earnings guidance for the full year 2017, first quarter of 2018 and full year of 2018. For the full year 2017, the company anticipates total revenue of $555 million to $560 million the midpoint of which represents a $69 million or 14% increase from 2016, compare to $540 million to $560 million previously announced guidance. Anticipated Pre-Tax income of $113 million to $117 million. Anticipated net income of $80 to $84 million, the midpoint of which represents a $20 million or 32% increase from 2016, compare to $70 million to $80 million previously announced guidance. Anticipated adjusted net income of $92 million to $96 million compare to $85 million to $95 million previously announced guidance. Anticipated EBITDA of $160 million to $164 million compare to $150 million to $160 million previously announced guidance.

For the first quarter of 2018, the company anticipates total revenues of $145 million to $160 million.

For the full year of 2018, the company expects total revenue to be in the range of $715 million to $755 million. Pre-Tax Income guidance is expected to be in the range of $120 million to $140 million. Net Income guidance is expected to be in the range of $95 million to $110 million. Adjusted Net Income guidance is expected to be in range of $110 million to $125. EBITDA guidance is expected to be in range of $175 million to $190 million.